PEOPLE - Changes at Myriad Genetics:
This article was originally published in Clinica
Salt Lake City, Utah-based Myriad Genetics, a biopharmaceutical organisation specialising in the use of proteomic and genomic technologies to create medical, diagnostic and therapeutic products, has selected John Henderson as chairman of the board. Linda Wilson has been appointed to the audit committee. Dr Henderson has been a director of Myriad since 2004, and will lead the company's commercialisation of its new Alzheimer's, cancer and AIDS-related products. Dr Wilson has been a Myriad director since 1999. Both positions arose on the death of board chairman and audit committee member Dale Stringfellow.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.